Stimwave Technologies Inc: Business Overview, Financials & Competitive Analysis
Stimwave Technologies Inc scores 3/10 on the AskCyborg Cyborg Score (Challenged). Asset acquisition post-bankruptcy allows technology continuation under new ownership, but reputational damage and regulatory scrutiny severely limit growth potential and investor appeal. The SEC charged former CEO and co-founder Laura Tyler Perryman with defrauding investors of approximately $41 million through false statements about the PNS device, and after fraud.
What is Stimwave Technologies Inc's industry? Stimwave Technologies Inc (stimwavefreedom.com) operates in Neurostimulation Devices. AskCyborg classifies Stimwave Technologies Inc under Neurostimulation Devices in its company registry.
Stimwave Technologies develops and markets wireless microsize injectable medical devices for neurology markets, focusing on peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) for chronic pain managem...
Cyborg Score thesis
Asset acquisition post-bankruptcy allows technology continuation under new ownership, but reputational damage and regulatory...
Read the full analyst-debate transcript →Get the Latest Stimwave Technologies Inc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeStimwave Technologies Inc Overview
Pro stress-test →Stimwave Technologies develops and markets wireless microsize injectable medical devices for neurology markets, focusing on peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) for chronic pain management. However, the company has undergone significant restructuring following major governance and regulatory challenges.
Strategic Profile
Pro stress-test →Stimwave filed Chapter 11 bankruptcy on June 15, 2022, with assets purchased by Curonix LLC on October 31, 2022. Its PNS and SCS products are implanted technology that block pain signals to the brain and provide a drug-free alternative for treating chronic pain. The company's core technology platform remains clinically relevant, but operational continuity and investor confidence remain challenged.
Competitive Landscape
Pro stress-test →Main competitors include NeuroPace, OrthAlign, Primo Medical Group, and Galt Medical. The neuromodulation market for chronic pain treatment is competitive, with multiple FDA-cleared implantable devices and established market players. Stimwave's post-bankruptcy status places it in a recovery/rebuilding position relative to more stable competitors.
Industry Context
Stimwave Technologies Inc operates in Neurostimulation Devices.
Key facts
Founded: 2010 · Headquarters: Pompano Beach, FL, United States · Employees: Unknown · Revenue: N/A · Market cap: N/A